Dear Editor,
We read with interest the article on coronavirus disease 2019 (COVID-19) recently published in Korean Journal of Radiology (1). In this letter, we share our experience on the evolution of computed tomography (CT) findings in COVID-19 pneumonia. An outbreak of COVID-19 that began in Wuhan, China, has spread rapidly (2,3,4). As of February 15, 2020, China has reported 68584 patients, including 1666 fatalities (5). Moreover, multiple countries reporting imported cases from China are rapidly increasing (6). The disease poses a grave threat to global public health, with the need for close attention.
Five patients admitted to Taizhou Hospital of Wenzhou Medical University between January 17 and January 29, 2020 were diagnosed with COVID-19 by real-time-polymerase chain reaction. Two patients were men and three patients were women, with a median age of 45 years (range 20–55 years). All five patients had a history of travel to Wuhan. The initial symptoms of the patients were fever (n = 4), cough (n = 3), diarrhea (n = 1), and pharyngodynia (n = 1). All patients had normal serum levels of white blood cell count on admission; however, two of the five patients had lymphocytes below the normal range (1.0 × 109/L, 0.3 × 109/L). In addition, increased C-reactive protein levels (median 20.98 mg/L, range 9.23–287.50 mg/L) were observed in four of the five patients. On admission, all five patients had abnormalities on chest CT images. The typical manifestations on initial chest CT images were multiple ground-glass opacities with or without patchy consolidation (Figs. 1, 2, 3, 4, 5). Four patients (Figs. 2, 3, 4, 5) had bilateral involvement and the subpleural regions were the commonly involved areas (Figs. 1, 2, 3, 4). All patients were treated in isolation. Five patients received antiviral treatment (lopinavir and ritonavir, interferon alfa-2b injection, and arbidol hydrochloride), four patients were administered antibiotic treatment (azithromycin, levofloxacin, piperacillin sodium and sulbactam sodium, and imipenem and cilastatin sodium). Other treatments provided included: traditional Chinese medicine (n = 3), cortisol hormone (n = 2), immune globulin (n = 1), oxygen therapy (n = 2), and mechanical ventilation (n = 3).
All five patients showed marked improvement in chest radiographic abnormalities after active intervention. On the early and mid-term follow-up CTs, Two patients (Figs. 3A–F, 4A–F) showed an increase in the extent and density of consolidations, whereas one patient (Fig. 2A–F) showed a lesser extent of consolidation but more ground-glass opacities. On the late follow-up CT, one patient (Fig. 1) showed consolidations that had been completely resolved and four patients (Figs. 2, 3, 4, 5) showed significantly reduced consolidations; however, in one patient, small amounts of patchy ground-glass opacities and fibrous stripes in bilateral lungs still persisted (Fig. 5). As of February 19, 2020, all five patients had successfully recovered and discharged. Fitness for discharge (7) included body temperature returning to normal for at least three consecutive days, significant improvement of acute exudative lesions on chest CT imaging, and viral clearance in respiratory samples from the upper respiratory tract (two consecutive negative results of COVID-19).
References
- 1.Lin X, Gong Z, Xiao Z, Xiong J, Fan B, Liu J. Novel coronavirus pneumonia outbreak in 2019: computed tomographic findings in two cases. Korean J Radiol. 2020;21:365–368. doi: 10.3348/kjr.2020.0078. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Jan 29; doi: 10.1056/NEJMoa2001316. [Epub] [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected, interim guidance. World Health Organization Web site. [Accessed February 15, 2020]. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Published January 12, 2020.
- 4.Tian HY. [2019-nCoV: new challenges from coronavirus] Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54:E001. doi: 10.3760/cma.j.issn.0253-9624.2020.0001. [DOI] [PubMed] [Google Scholar]
- 5.By 24:00 on February 15, 2020, the latest developments of coronavirus disease 2019. National Health Commission of the People's Republic of China Web site. [Accessed February 16, 2020]. http://www.nhc.gov.cn. Published February 16, 2020.
- 6.Nishiura H, Jung SM, Linton NM, Kinoshita R, Yang Y, Hayashi K, et al. The extent of transmission of novel coronavirus in Wuhan, China, 2020. J Clin Med. 2020;9:330. doi: 10.3390/jcm9020330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Working Group of 2019 Novel Coronavirus; Peking Union Medical College Hospital. [Diagnosis and clinical management of 2019 novel coronavirus infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)] Zhonghua Nei Ke Za Zhi. 2020;59:186–188. doi: 10.3760/cma.j.issn.0578-1426.2020.03.003. [DOI] [PubMed] [Google Scholar]